Retinitis pigmentosa (RP) is a group of hereditary retinal disorders (HRDs) that affect nearly 1 in 4000 people worldwide [
1]. However, the prevalence of RP varies across world populations, and the condition being highly frequent in the South Asian countries (1/930 in South India, 1/1000 in Northern China [
2,
3]. RP typically appears with a loss of peripheral vision causing visual field constriction (tunnel vision) followed by central vision loss, and eventually leads to complete blindness though visual acuity may remain unaffected during the whole course of the disease. These symptoms are mainly due to progressive degeneration of rods and cones photoreceptors cells of the retina [
4,
5]. As of today, mutations in at least 89 genes have been reported in RP patients following all modes of Mendelian inheritance, including autosomal dominant (AD), autosomal recessive (AR), X-linked, and mitochondrial or digenic inheritance (RetNet: https:/sph.uth.edu; accessed on 18 February 2022).
Phosphodiesterase 6 (PDE6) remains integral to the vertebrate phototransduction pathway because it regulates the cytoplasmic level of cyclic guanosine monophosphate (cGMP) in the photoreceptors [
6]. It comprises a total of four subunits, including, a catalytic alpha-subunit
PDE6A (MIM # 613810), a catalytic beta subunit
PDE6B (MIM # 163500, 613801), and two inhibitory gamma-subunits
PDE6G (MIM # 613582) [
7,
8]. The enzyme hydrolyzes the intracellular cytoplasmic cGMP level [
9]. Consequently, low level of cGMP leads to the closure of ion channels and therefore membrane hyperpolarization [
10]. The gene encoding the beta subunit of PDE6 (
PDE6B) was one of the foremost genes known to cause retinal degeneration in mice, dogs, and humans [
7,
8].
PDE6B harbors a 45-Mb region on human chromosome 4p16.3 and is composed of 22 exons, which give rise to several splice isoforms, ranging in length from 2.7 to 3.4 Kb [
11]. Loss-of-function (LoF) mutations in the
PDE6B gene lead to dysfunction of the PDE6 holoenzyme and an accumulation of cGMP and Ca
2+ in the rod photoreceptor cells. Accumulations of cGMP and Ca
2+ lead to degeneration of rods followed by cone cells through apoptosis consequently leading to blindness. Recessive bi-allelic mutations in
PDE6B are a common cause of autosomal recessive RP (arRP) in various populations [
11,
12]. Nevertheless, heterozygous dominant mutations in the
PDE6B gene cause AD congenital stationary night blindness [
13]. Among patients with arRP, ~ 5–8% cases are known to have defects in rod-specific cyclic guanosine monophosphate (cGMP) phosphodiesterase 6β subunits (
PDE6B) [
14]. Similarly, mutations in the
PDE6B homolog (NM_000283.3) have been known to cause rod and cone degeneration in animal models [
6,
15].
Molecular diagnosis of RP in clinical practice has been greatly facilitated, thanks to recent advances in next-generation sequencing (NGS) technologies, notably, whole-exome sequencing (WES) and whole-genome sequencing (WGS) [
16]. Today, ophthalmic examinations coupled with NGS are considered as the most suitable technique for the molecular diagnosis of RP [
5,
8]. Treatment options for
PDE6B-related RP are currently not available; however, proof-of-concept studies with sub-retinal gene therapy showed positive effects in mice and dogs when treated at a very early time during postnatal development of the retina [
17,
18]. A clinical trial on the safety and efficacy of gene therapy in human patients with RP caused by bi-allelic mutations in the
PDE6B gene is currently ongoing (ClinicalTrials.gov Identifier: NCT03328130). Similarly, transplantation of chemically induced photoreceptor-like cells (CiPCs) into the sub-retinal space of
rd1 mice, which were homozygous mutants for
Pde6b, showed a partial restoration of the pupil reflex and visual function [
19]. In this study, we document clinical and molecular findings in a consanguineous Pakistani family segregating
PDE6B-related RP.